GWM
ASMB icon

Geneos Wealth Management’s Assembly Biosciences ASMB Stock Holding History

Geneos Wealth Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-21
Closed -$9K – 2381
2018
Q3 		$9K Buy
+21
New +$9.84K ﹤0.01% 1863

Other funds holding ASMB

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Geneos Wealth Management's ASMB Position: Q4 2018 in Review

Geneos Wealth Management sold out of Assembly Biosciences (ASMB) in Q4 2018, closing a stake of 21 shares — an estimated $9K sold.

Geneos Wealth Management first reported a position in ASMB in Q3 2018 and held it in 1 quarter. The position peaked at $9K in Q3 2018. 106 funds tracked by Wall St. Rank hold ASMB as of Q4 2018.

  • Geneos Wealth Management reported no remaining Assembly Biosciences position as of Q4 2018 after selling out during the quarter.
  • Geneos Wealth Management sold 21 Assembly Biosciences shares in Q4 2018, an estimated $9K.
  • Geneos Wealth Management first reported a position in Assembly Biosciences in Q3 2018 and held it in 1 quarter.
  • Geneos Wealth Management's Assembly Biosciences position peaked at $9K in Q3 2018.
  • 106 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2018.

Based on Geneos Wealth Management's 13F filing for Q4 2018, filed 7 Sep 2021.